Eagle Pharmaceuticals Analyst Ratings
Eagle Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/09/2023 | -15.34% | Piper Sandler | $26 → $17 | Downgrades | Neutral → Underweight |
| 03/02/2020 | 129.08% | Cantor Fitzgerald | $58 → $46 | Maintains | Neutral |
| 03/22/2019 | 104.18% | Mizuho | $40 → $41 | Maintains | Neutral |
| 10/31/2018 | 168.92% | Piper Sandler | $82 → $54 | Downgrades | Overweight → Neutral |
| 09/21/2018 | 298.41% | Cantor Fitzgerald | $81 → $80 | Maintains | Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变化 | 评级变化 | 上一次/当前评级 |
|---|---|---|---|---|---|
| 08/09/2023 | -15.34% | 派珀·桑德勒 | $26→$17 | 评级下调 | 中性→减持 |
| 03/02/2020 | 129.08% | 康托·菲茨杰拉德 | $58→$46 | 维护 | 中性 |
| 2019/03/22 | 104.18% | 瑞穗 | $40→$41 | 维护 | 中性 |
| 2018年10月31日 | 168.92% | 派珀·桑德勒 | $82→$54 | 评级下调 | 超重→中性 |
| 2018年09月21日 | 298.41% | 康托·菲茨杰拉德 | $81→$80 | 维护 | 超重 |
What is the target price for Eagle Pharmaceuticals (EGRX)?
Eagle PharmPharmticals(EGRX)的目标价是多少？
The latest price target for Eagle Pharmaceuticals (NASDAQ: EGRX) was reported by Piper Sandler on August 9, 2023. The analyst firm set a price target for $17.00 expecting EGRX to fall to within 12 months (a possible -15.34% downside). 1 analyst firms have reported ratings in the last year.
派珀·桑德勒于2023年8月9日报道了鹰制药(纳斯达克代码：EGRX)的最新目标价。这家分析公司将目标价定为17.00美元，预计EGRX将在12个月内降至(可能下跌15.34%)。1家分析公司在过去一年公布了评级。
What is the most recent analyst rating for Eagle Pharmaceuticals (EGRX)?
分析师对鹰制药(Eagle PharmPharmticals)的最新评级是多少？
The latest analyst rating for Eagle Pharmaceuticals (NASDAQ: EGRX) was provided by Piper Sandler, and Eagle Pharmaceuticals downgraded their underweight rating.
分析师对鹰制药(纳斯达克代码：EGRX)的最新评级由Piper Sandler提供，鹰制药下调了其减持评级。
When is the next analyst rating going to be posted or updated for Eagle Pharmaceuticals (EGRX)?
Eagle PharmPharmticals(EGRX)的下一次分析师评级将于何时发布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Eagle Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Eagle Pharmaceuticals was filed on August 9, 2023 so you should expect the next rating to be made available sometime around August 9, 2024.
分析师在进行了广泛的研究后得出了股票评级，其中包括查阅公共财务报表，与Eagle PharmPharmticals的高管和客户交谈，以及听取收益电话会议。大多数分析师每三个月就会这样做一次，所以你每年应该会得到每家公司每家公司的4个评级。Eagle PharmPharmticals的上一次评级是在2023年8月9日提交的，所以你应该预计下一次评级将在2024年8月9日左右提供。
Is the Analyst Rating Eagle Pharmaceuticals (EGRX) correct?
分析师对Eagle PharmPharmticals(EGRX)的评级正确吗？
While ratings are subjective and will change, the latest Eagle Pharmaceuticals (EGRX) rating was a downgraded with a price target of $26.00 to $17.00. The current price Eagle Pharmaceuticals (EGRX) is trading at is $20.08, which is out of the analyst's predicted range.
虽然评级是主观的，并将发生变化，但最新的Eagle PharmPharmticals(EGRX)评级为下调，目标价为26.00美元至17.00美元。Eagle PharmPharmticals(EGRX)目前的股价为20.08美元，超出了分析师的预测区间。